The nation of Zimbabwe has turned down a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on confidential biological samples.
The decision came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman has since explained that the United States was requesting genetic material for research and profit while was unwilling to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for further talks to find a agreement acceptable to both sides so the nation's critical HIV programme can proceed.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of Kenyans' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and accountability.
According to statements, Sixteen African countries have so far signed similar agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our population if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting frameworks already established through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This framework is designed to guarantee that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We encourage ongoing discussions with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes depended on external financing.
"If specific concerns arise, such as those relating to information security or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group commented.
This impasse emphasises the complex debate between accepting vital foreign assistance and safeguarding a country's data in an ever more interconnected world.